Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Current Leases (2019 - 2025)

Silence Therapeutics' Current Leases history spans 7 years, with the latest figure at $89000.0 for Q4 2025.

  • On a quarterly basis, Current Leases fell 23.93% to $89000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $89000.0, a 23.93% decrease, with the full-year FY2025 number at $89000.0, down 23.93% from a year prior.
  • Current Leases hit $89000.0 in Q4 2025 for Silence Therapeutics, up from $85000.0 in the prior quarter.
  • Over the last five years, Current Leases for SLN hit a ceiling of $523126.0 in Q4 2022 and a floor of -$588095.6 in Q3 2022.
  • Historically, Current Leases has averaged -$99006.1 across 5 years, with a median of -$180598.6 in 2021.
  • Biggest five-year swings in Current Leases: tumbled 1243.29% in 2021 and later soared 183.26% in 2022.
  • Tracing SLN's Current Leases over 5 years: stood at $184677.5 in 2021, then soared by 183.26% to $523126.0 in 2022, then plummeted by 142.47% to -$222166.2 in 2023, then soared by 152.66% to $117000.0 in 2024, then fell by 23.93% to $89000.0 in 2025.
  • Business Quant data shows Current Leases for SLN at $89000.0 in Q4 2025, $85000.0 in Q3 2025, and $60000.0 in Q1 2025.